FORT LAUDERDALE, Fla. — A senolytic therapy represents a novel approach to treating diabetic macular edema and wet age-related macular degeneration, according to a speaker at the Retina World Congress. Raj Maturi, MD, presented data from a phase 1 study exploring the safety and efficacy of UBX1325 (Unity Biotechnology).
